

**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**Incorporated in the Republic of the Union of Myanmar,**  
**Registration Number 148900353**

**FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED MARCH 31, 2024**

Currency – Myanmar Kyat (MMK)

**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED MARCH 31, 2024**

<b>CONTENTS</b>	<b>PAGE</b>
Statement of Management's Responsibility	1
Independent Auditor's Report	2 - 3
Statement of Financial Position	4
Statement of Comprehensive Income	5
Statement of Changes in Equity	6
Statement of Cash Flows	7
Notes to the Financial Statements	8 - 22

Regd. Office :

Lot No B19, Zone A,  
Thilawa special economic zone,  
Thanlyin Township, Yangon,  
Myanmar.


**STATEMENT OF MANAGEMENT'S RESPONSIBILITY  
ALIDAC HEALTHCARE (MYANMAR) LIMITED**

It is the responsibility of the management to prepare the financial statements which give a true and fair view of the state of affairs of **Alidac Healthcare (Myanmar) Limited** (the "Company") as at March 31, 2024 and of its financial performance and its cash flows for the year then ended and a summary of significant accounting policies and other explanatory notes. In preparing these financial statements, the management is required to:

- Select suitable accounting policies and then apply them consistently; and
- Make judgments and estimates that are reasonable and prudent.

The management is responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Company. We, the management committee, have general responsibility for taking such steps as are reasonably open to us to safeguard the assets of the Company and to prevent and detect fraud and other irregularities.

On behalf of Management



May 17, 2024

Kailash Badoni  
Director

Alidac Healthcare (Myanmar) Limited.



May 17, 2024

Gulshan Arora  
Director

Alidac Healthcare (Myanmar) Limited



ဝင်းသင်နှင့်အဖွဲ့လီမိတက်

**WIN THIN & ASSOCIATES LTD**

CERTIFIED PUBLIC ACCOUNTANTS

Room (2B/2C) 1<sup>st</sup> Floor, Rose Condominium, No. 182/194, Botahtaung Pagoda Road, Pazundaung Township, Yangon Region, Myanmar. Tel: 95-1-8201798, 8296164, Fax: 95-1-8245671 Email: info@winthinassociates.com

---

**Ref: 85 (a)/ A-148 / March 2024**

## **INDEPENDENT AUDITOR'S REPORT**

**To the members of Alidac Healthcare (Myanmar) Limited**

### **Report on the Audit of the Financial Statements**

#### **Opinion**

We have audited the financial statements of **Alidac Healthcare (Myanmar) Limited** (“the Company”), which comprise the statement of financial position as at March 31, 2024, and the statements of comprehensive income, changes in equity and cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as at March 31, 2024, and its financial performance and its cash flows for the year then ended in accordance with Myanmar Financial Reporting Standards (“MFRSs”) and the provisions of the Myanmar Companies Law (the “Law”).

#### **Basis for Opinion**

We conducted our audit in accordance with International Standards on Auditing (“ISAs”). Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Myanmar, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Responsibilities of Management and Those Charged with Governance for the Financial Statements**

Management is responsible for the preparation and fair presentation of the financial statements in accordance with MFRSs and the provisions of the Law, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease the operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company’s financial reporting process.

## **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:


- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

## **Report on Other Legal and Regulatory Requirements**

In accordance with the provisions of the Law, we also report that:

- (i) we have obtained all the information and explanations we have required; and
- (ii) financial records have been maintained by the Company as required by Section 258 of the Law.

  
Kyaw Tun Aung (PAPP - 479)  
Partner  
WIN THIN & ASSOCIATES LTD  
CERTIFIED PUBLIC ACCOUNTANTS  
Firm Registration No. ACC 008



May 17, 2024

**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**STATEMENT OF FINANCIAL POSITION**  
**AS AT MARCH 31, 2024**


	Notes	2024 MMK	2023 MMK
<b>ASSETS</b>			
<b>Non-current assets</b>			
Property, plant and equipment	4	19,450,107,828	20,156,945,449
Intangible assets	5	4,602,711	5,957,337
		<u>19,454,710,539</u>	<u>20,162,902,786</u>
<b>Current assets</b>			
Inventories	6	10,193,531,213	7,522,514,154
Trade and other receivables	7	10,042,095,955	5,365,146,486
Cash and cash equivalents	8	38,063,766,539	13,519,392,600
		<u>58,299,393,707</u>	<u>26,407,053,240</u>
<b>Total assets</b>		<u>77,754,104,246</u>	<u>46,569,956,026</u>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Paid-up capital	9	43,780,641,000	43,780,641,000
Retained earnings		(18,419,439,607)	(10,570,871,728)
		<u>25,361,201,393</u>	<u>33,209,769,272</u>
<b>Non-current liabilities</b>			
Borrowing	10	20,839,986,822	6,621,313,922
		<u>20,839,986,822</u>	<u>6,621,313,922</u>
<b>Current liabilities</b>			
Borrowing	10	—	—
Trade and other payables	11	31,552,916,031	6,738,872,832
		<u>31,552,916,031</u>	<u>6,738,872,832</u>
<b>Total equity and liabilities</b>		<u>77,754,104,246</u>	<u>46,569,956,026</u>

*The accompanying notes form an integral part of these financial statements.*

**Authenticated by:**

(1)

(2)



Kailash Badoni  
 Director

Alidac Healthcare (Myanmar) Limited.



Gulshan Arora  
 Director

Alidac Healthcare (Myanmar) Limited

**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**STATEMENT OF COMPREHENSIVE INCOME**  
**FOR THE YEAR ENDED MARCH 31, 2024**

	Note	2024 MMK	2023 MMK
<b>INCOME</b>			
Revenue from operations	12	38,553,359,871	22,861,298,326
Other income	13	2,164,965,461	549,305,008
<b>Total income</b>		<b>40,718,325,332</b>	<b>23,410,603,334</b>
<b>EXPENSES</b>			
Cost of materials consumed	14	8,265,472,411	5,464,852,792
Change in inventories of finished goods and work in progress	15	(420,057,350)	(628,536,480)
Employee benefits expense	16	2,326,567,494	1,793,595,954
Finance costs	17	9,846,581,545	462,543,090
Depreciation and amortization expense	4/5	1,229,505,692	1,297,120,397
Other expenses	18	27,318,823,419	9,594,932,409
<b>Total expenses</b>		<b>48,566,893,211</b>	<b>17,984,508,162</b>
<b>(Loss)/profit before income tax</b>		<b>(7,848,567,879)</b>	5,426,095,172
Income tax expense		—	—
<b>(Loss)/profit for the year</b>		<b>(7,848,567,879)</b>	5,426,095,172
Other comprehensive income for the year		—	—
<b>Total comprehensive income for the year</b>		<b>(7,848,567,879)</b>	5,426,095,172

*The accompanying notes form an integral part of these financial statements.*

**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**STATEMENT OF CHANGES IN EQUITY**  
**FOR THE YEAR ENDED MARCH 31, 2024**

	Paid-up capital MMK	Retained earnings MMK	Total MMK
Balance at April 1, 2023	43,780,641,000	(10,570,871,728)	33,209,769,272
Loss for the year	–	(7,848,567,879)	(7,848,567,879)
Other comprehensive income for the year	–	–	–
<b>Balance at March 31, 2024</b>	<b>43,780,641,000</b>	<b>(18,419,439,607)</b>	<b>25,361,201,393</b>
Balance at April 1, 2022	43,780,641,000	(15,996,966,900)	27,783,674,100
Profit for the year	–	5,426,095,172	5,426,095,172
Other comprehensive income for the year	–	–	–
<b>Balance at March 31, 2023</b>	<b>43,780,641,000</b>	<b>(10,570,871,728)</b>	<b>33,209,769,272</b>

*The accompanying notes form an integral part of these financial statements.*



**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**STATEMENT OF CASH FLOWS**  
**FOR THE YEAR ENDED MARCH 31, 2024**

	Note	2024 MMK	2023 MMK
<b>Cash flows from operating activities:</b>			
(Loss)/profit before income tax		(7,848,567,879)	5,426,095,172
Adjustments for:			
Depreciation and amortization expense	4/5	1,229,505,692	1,297,120,397
Profit on disposal: property, plant and equipment		–	(53,481)
Foreign exchange loss on borrowing	10	9,276,848,376	309,337,389
Interest expenses	17	559,301,989	139,708,381
Interest income	13	(2,003,590,608)	(432,782,595)
Operating profit before working capital changes		1,213,497,570	6,739,425,263
Changes in working capital:			
(Increase) in inventories		(2,671,017,059)	(1,498,813,283)
(Increase) in trade and other receivables		(3,875,764,880)	(1,504,157,719)
Increase in trade and other payables		24,254,741,210	5,325,877,805
Cash generated from operations		18,921,456,841	9,062,332,066
Income tax paid		–	–
Net cash inflow from operating activities		18,921,456,841	9,062,332,066
<b>Cash flows from investing activities:</b>			
Additions to property, plant and equipment	4	(520,378,445)	(1,289,964,529)
Additions to intangible assets	5	(935,000)	(5,775,000)
Proceeds from disposal of property, plant and equipment		–	333,459
Interest income received		1,202,406,019	360,266,156
Net cash inflow (outflow) from investing activities		681,092,574	(935,139,914)
<b>Cash flows from financing activities:</b>			
Additions to borrowing	10	4,941,824,524	2,141,876,533
Net cash provided by financing activities		4,941,824,524	2,141,876,533
<b>Net increase in cash and cash equivalents</b>		<b>24,544,373,939</b>	<b>10,269,068,685</b>
<b>Cash and cash equivalents</b>			
Beginning of year		13,519,392,600	3,250,323,915
<b>End of year</b>	8	<b>38,063,766,539</b>	<b>13,519,392,600</b>

*The accompanying notes form an integral part of these financial statements.*

**ALIDAC HEALTHCARE (MYANMAR) LIMITED  
NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED MARCH 31, 2024**

These notes form an integral part of and should be read in conjunction with the accompanying financial statements.

**1. General information**

Alidac Healthcare (Myanmar) Limited (the “Company”) was incorporated in the Republic of the Union of Myanmar as per renewed Certificate of Incorporation Number 148900353 {Former Registration No. 7FC of 2016-2017 (TSEZ)} on June 17, 2016 as 100% foreign company under the Myanmar Special Economic Zone Law of 2014 and the Myanmar Companies Law upon obtaining Investment Permit No. TSEZ-IP-058-R-1 dated May 20, 2016 issued by the Thilawa Special Economic Zone Management Committee under Section 11 (c) of the Myanmar Special Economic Zone Law of 2014.

The principal activities of the Company are the manufacturing and selling of pharmaceutical products.

The address of its registered office is Lot No. B19, Zone A, Thilawa SEZ, Thanlyin Township, Yangon Region, Republic of the Union of Myanmar.

The Company started its commercial operation on October 1, 2020.

**2. Summary of significant accounting policies**

The principal accounting policies applied in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

**2.1 Basis of preparation**

The accompanying financial statements have been prepared in accordance with Myanmar Financial Reporting Standards and are based on historical cost convention. In preparation of these financial statements, certain reclassifications and rearrangements have been made in previous year to conform to the classifications used in current year.

**2.2 Foreign currency translation**

**2.2.1 Functional and presentation currency**

Items included in the financial statements of the Company are measured using the currency of primary economic environment in which the entity operates (the “functional currency”). The financial statements are presented in Myanmar Kyat (MMK), which is the presentation currency as well as functional currency of the Company.

**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED MARCH 31, 2024**

**2. Summary of significant accounting policies** (continued)

2.2.2 Transactions and balances

Transactions in foreign currencies (USD) are recorded in MMK at the CBM reference exchange rate (i.e., USD 1 = MMK 2,100) for the period from April 2023 to December 2023 and the CBM online trading rate (i.e., USD 1 = approximately MMK 3,400) for the period from January 2024 to March 2024.

Monetary assets and liabilities denominated in USD at the end of the reporting period are translated into MMK at the prevailing market rate (i.e., USD 1 = MMK 3,850) at the end of the reporting period.

Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement.

**2.3 Property, plant and equipment**

Property, plant and equipment are initially recognized at cost and subsequently carried at cost less accumulated depreciation and any accumulated impairment losses.

The cost of maintenance and minor repairs are charged to income as incurred. Significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the income statement.

Depreciation on all tangible assets is calculated using the straight-line method to allocate their 95% of total cost over their estimated useful lives as follows:

<u>Description</u>	<u>Useful lives</u>
Furniture and fitting	10 years
Office equipment	3 years
Motor vehicles	8 years
Leasehold land	48 years
Factory buildings	30 years
Plant and equipment single shift	15 years
Plant and equipment two shift	10 years

The assets' useful lives are reviewed, and adjusted prospectively if appropriate, if there is any indication of a significant change since the last reporting date.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Any gain or loss of disposal of an item of property, plant and equipment is recognized within "other gains/(losses) - net" in the statement of comprehensive income.

**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED MARCH 31, 2024**

**2. Summary of significant accounting policies (continued)**

**2.4 Intangible assets**

Acquired computer software licenses are initially capitalized at cost which includes the purchase price (net of any discounts and rebates) and other directly attributable costs of preparing the asset for its intended use. Direct expenditures including employee costs, which enhance or extend the performance of computer software beyond its specifications and which can be reliably measured, are added to the original cost of the software. Costs associated with maintaining the computer software are expensed off when incurred.

Computer software licenses are subsequently carried at cost less accumulated amortization and accumulated impairment losses. These costs are amortized to profit or loss using the straight-line method over their estimated useful lives of 4 years (25%).

**2.5 Inventories**

Inventories are valued at the lower of cost and net realizable value. Costs incurred in bringing each product to its present location and condition are accounted for as follows:

- a) Raw materials, packing materials, finished goods, and works-in-progress are valued at lower of cost and net realizable value.
- b) Cost of raw materials, packing materials, finished goods and stock-in-trade is determined on moving average method.
- c) Costs of finished goods and work-in-progress are determined by taking material cost, labour and relevant appropriate overheads based on the normal operating capacity but excluding borrowing costs.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

Write down of inventories to net realizable value is recognized as an expense and included in “Changes in Inventories of Finished goods, Work-in-progress and Stock-in-Trade” and “Cost of Materials Consumed” in the relevant note in the statement of comprehensive income.

**2.6 Trade receivables**

Trade receivables are initially recognized at fair value and subsequently measured at amortized cost using the effective interest method, less provision for impairment. Appropriate allowances for estimated irrecoverable amounts are recognized in profit or loss when there is objective evidence that the asset is impaired.

**2.7 Other receivables**

If collection of other receivables is expected in one year or less (or in the normal operating cycle of the business if longer), they are classified as current assets. If not, they are presented as non-current assets.

Other receivables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method, less any allowance for doubtful receivables based on a review of all outstanding amounts at the year-end.

**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED MARCH 31, 2024**

**2. Summary of significant accounting policies** (continued)

**2.8 Impairment of assets**

The Company assess whether there is an indication that any asset may be impaired. If any such indication exists, the Company makes an estimate of the asset recoverable amount. Where the carrying amount of the asset exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. Impairment losses are recognized in the statement of comprehensive income. An asset recoverable amount is the higher of fair value less costs to sell and value in use.

**2.9 Cash and cash equivalents**

For the purpose of presentation in the statement of cash flows, cash and cash equivalents include cash in hand, balance with banks and deposits with banks.

**2.10 Paid-up capital**

Ordinary shares are classified as equity.

**2.11 Loans**

Loans are presented as current liabilities unless the Company has an unconditional right to defer settlement for at least 12 months after the balance sheet date, in which case they are presented as non-current liabilities.

Loans are initially recognized at fair value (net of transaction costs) and subsequently carried at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption value is recognized in profit or loss over the period of loan using the effective interest method.

**2.12 Borrowing costs**

Borrowing costs consist of interest and other borrowing costs that are incurred in connection with the borrowing of funds. Other borrowing costs include ancillary charges at the time of acquisition of a financial liability, which is recognized as per EIR method. Borrowing costs also include exchange differences to the extent regarded as an adjustment to the borrowing costs.

Borrowing costs that are directly attributable to the acquisition/construction of a qualifying asset are capitalized as part of the cost of such assets, up to the date the assets are ready for their intended use.

**2.13 Trade and other payables**

Trade and other payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Other payables are classified as current liabilities if payment is due within one year or less (or in the normal operating cycle of the business if longer). If not, they are presented as non-current liabilities.

Trade and other payables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method.

**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED MARCH 31, 2024**

**2. Summary of significant accounting policies** (continued)

**2.14 Provisions, contingent liabilities and contingent assets**

Provisions are recognized when the Company has a present obligation as a result of past events and it is probable that the outflow of resources will be required to settle the obligation and in respect of which reliable estimates can be made. A disclosure for contingent liability is made when there is a possible obligation, that may, but probably will not require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision/ disclosure is made. Contingent assets are not recognized but are disclosed separately in the financial statements.

Provisions and contingencies are reviewed at each balance sheet date and adjusted to reflect the correct management estimates. Contingent assets are not recognized but are disclosed separately in financial statements.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate the risks specific to the liability.

**2.15 Revenue recognition**

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured at the fair value of consideration received or receivable.

*Revenue from sale of goods*

Revenue from sale of goods is recognised upon the transfer of significant risk and rewards of ownership of the goods to the customers. Revenue is not recognized to the extent where there are significant uncertainties regarding recovery of the consideration due, associated costs or the possible return of goods.

**2.16 Leases**

**As a lessee**

Leases are classified as finance leases whenever the terms of leases transfers substantially all the risks & rewards of the ownership to the lessee. All other leases are classified as operating leases.

**Operating leases**

Operating leases payments are recognized as expenses on straight-line basis over the lease terms, except if another systematic basis is more representative of the time pattern in which economic benefits will flow to the company.

**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED MARCH 31, 2024**

**2. Summary of significant accounting policies** (continued)

**2.17 Employee benefits**

**Short-term obligations**

Liabilities for wages and salaries, including leave encashment that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees' services up to the end of the reporting and are measured by the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet.

**3. Significant accounting judgments and estimates**

The preparation of the Company's financial statements in conformity with MFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the end of each reporting period. However, uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amount of the asset or liability affected in the future periods.

**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED MARCH 31, 2024**

**4. Property, plant and equipment**

	Leasehold land MMK	Factory building MMK	Plant and Equipment MMK	Furniture and fitting MMK	Office equipment MMK	Total MMK
<i>Cost</i>						
At April 1, 2023	3,698,967,495	6,916,559,426	12,697,672,435	146,846,221	354,361,349	23,814,406,926
Additions	–	–	446,588,436	6,853,029	66,936,980	520,378,445
Write-off	–	–	–	–	–	–
At March 31, 2024	<b>3,698,967,495</b>	<b>6,916,559,426</b>	<b>13,144,260,871</b>	<b>153,699,250</b>	<b>421,298,329</b>	<b>24,334,785,371</b>
<i>Accumulated depreciation and impairment losses</i>						
At April 1, 2023	(520,167,303)	(543,957,688)	(2,279,394,875)	(29,590,571)	(284,351,040)	(3,657,461,477)
Depreciation charge	(77,061,823)	(219,031,041)	(888,809,175)	(1,081,613)	(41,232,414)	(1,227,216,066)
Write-off	–	–	–	–	–	–
At March 31, 2024	<b>(597,229,126)</b>	<b>(762,988,729)</b>	<b>(3,168,204,050)</b>	<b>(30,672,184)</b>	<b>(325,583,454)</b>	<b>(4,884,677,543)</b>
<i>Net book value</i>						
<b>At March 31, 2024</b>	<b>3,101,738,369</b>	<b>6,153,570,697</b>	<b>9,976,056,821</b>	<b>123,027,066</b>	<b>95,714,875</b>	<b>19,450,107,828</b>
<i>Cost</i>						
At April 1, 2022	3,698,967,495	6,915,165,566	11,566,534,595	20,843,420	323,211,299	22,524,722,375
Additions	–	37,968,510	1,131,137,840	89,428,151	32,875,450	1,291,409,951
Transfer	–	(36,574,650)	–	36,574,650	–	–
Disposal	–	–	–	–	(1,725,400)	(1,725,400)
At March 31, 2023	3,698,967,495	6,916,559,426	12,697,672,435	146,846,221	354,361,349	23,814,406,926
<i>Accumulated depreciation and impairment losses</i>						
At April 1, 2022	(443,105,480)	(328,641,957)	(1,343,287,484)	(5,778,061)	(260,976,165)	(2,381,789,147)
Depreciation charge	(77,061,823)	(217,921,702)	(936,107,391)	(21,206,539)	(24,578,709)	(1,276,876,164)
Transfer	–	2,605,971	–	(2,605,971)	–	–
Disposal	–	–	–	–	1,203,834	1,203,834
At March 31, 2023	<b>(520,167,303)</b>	<b>(543,957,688)</b>	<b>(2,279,394,875)</b>	<b>(29,590,571)</b>	<b>(284,351,040)</b>	<b>(3,657,461,477)</b>
<i>Net book value</i>						
<b>At March 31, 2023</b>	<b>3,178,800,192</b>	<b>6,372,601,738</b>	<b>10,418,277,560</b>	<b>117,255,650</b>	<b>70,010,309</b>	<b>20,156,945,449</b>



**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED MARCH 31, 2024**

**5. Intangible assets**

Computer software license

	2024 MMK	2023 MMK
<i>Cost</i>		
At beginning of year	139,387,078	133,612,078
Additions	935,000	5,775,000
At end of year	<u>140,322,078</u>	<u>139,387,078</u>
<i>Accumulated amortization and impairment</i>		
At beginning of year	(133,429,741)	(111,981,674)
Amortization	(2,289,626)	(21,448,067)
At end of year	<u>(135,719,367)</u>	<u>(133,429,741)</u>
<b>Net book value</b>		
<b>At end of year</b>	<b><u>4,602,711</u></b>	<b><u>5,957,337</u></b>

**6. Inventories**

	2024 MMK	2023 MMK
Finished goods	3,426,870,754	3,068,694,661
Work-in-progress	61,881,257	-
Raw materials	6,189,460,835	3,744,116,068
Packing materials	515,318,367	709,703,425
	<u>10,193,531,213</u>	<u>7,522,514,154</u>

**7. Trade and other receivables**

	2024 MMK	2023 MMK
Trade receivables	7,282,668,874	3,962,180,866
Advance payments to suppliers	407,660,784	395,304,906
Advances to employees	342,018,947	89,685,818
Advance payments for house rental	88,750,000	98,579,800
Advance commercial tax	585,341,901	578,693,868
Prepayments	395,963,583	124,097,358
Deposits	31,575,500	14,065,500
Accrued interest income	873,701,027	72,516,438
Others	34,415,339	30,021,932
	<u>10,042,095,955</u>	<u>5,365,146,486</u>

**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED MARCH 31, 2024**

**8. Cash and cash equivalents**

	<b>2024</b>	2023
	<b>MMK</b>	MMK
Balances with banks	<b>1,693,060,939</b>	2,732,537,135
Fixed deposits	<b>36,350,000,000</b>	10,650,000,000
Cash in hand	<b>20,705,600</b>	136,855,465
	<b><u>38,063,766,539</u></b>	<u>13,519,392,600</u>

**9. Paid-up capital**

	<b>2024</b>		2023
	<b>Number of</b>	<b>Value of</b>	<b>Number of</b>
	<b>shares</b>	<b>shares</b>	<b>shares</b>
		<b>MMK</b>	<b>Shares</b>
			<b>MMK</b>
Beginning of year	<b>43,780,641</b>	<b>43,780,641,000</b>	43,780,641
Issue of shares	-	-	-
<b>End of year</b>	<b><u>43,780,641</u></b>	<b><u>43,780,641,000</u></b>	<u>43,780,641,000</u>

As at March 31, 2024, the share structure of the Company was as follows:

<b>Subscribers</b>	<b>2024</b>		2023
	<b>Number of</b>	<b>Value of</b>	<b>Number of</b>
	<b>shares</b>	<b>shares</b>	<b>shares</b>
		<b>MMK</b>	<b>Shares</b>
			<b>MMK</b>
Zydus Worldwide DMCC (ZWWD)	<b>43,780,641</b>	<b>43,780,641,000</b>	43,780,641
<b>End of year</b>	<b><u>43,780,641</u></b>	<b><u>43,780,641,000</u></b>	<u>43,780,641,000</u>

**10. Borrowing**

	<b>2024</b>	2023
	<b>MMK</b>	MMK
At beginning of year	<b>6,621,313,922</b>	4,170,100,000
Additions	<b>4,941,824,524</b>	2,141,876,533
Unrealized foreign exchange loss	<b>9,276,848,376</b>	309,337,389
	<b><u>20,839,986,822</u></b>	<u>6,621,313,922</u>
Repayments	-	-
<b>At end of year</b>	<b><u>20,839,986,822</u></b>	<u>6,621,313,922</u>

In March 2022, the Company has entered a long term offshore unsecured borrowing arrangement with its parent company Zydus World Wide DMCC to repay the Company's overdue of imports as the Company was not able to convert local currency into USD due to regulatory forex restrictions. The loan is still not repaid as the forex restrictions are still continue.

**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED MARCH 31, 2024**

**10. Borrowing (continued)**

	2024 MMK	2023 MMK
Current portion	–	–
Non-Current portion	<u>20,839,986,822</u>	<u>6,621,313,922</u>
	<u>20,839,986,822</u>	<u>6,621,313,922</u>

**11. Trade and other payables**

	2024 MMK	2023 MMK
Trade payables		
- ZLL-Trade Payable	27,790,707,714	4,545,466,275
- ZWWD-Interest Payable	1,228,766,346	142,023,187
- Others	1,130,218,637	1,146,286,673
Other payables		
- Payable to Government	31,610,806	40,166,700
- Payable to employees	578,754,048	187,369,711
- Provisions	792,858,480	677,560,286
	<u>31,552,916,031</u>	<u>6,738,872,832</u>

**12. Revenue from operations**

The above represent revenue from manufacturing and selling of pharmaceutical products for the year ended March 31, 2024 amounting to **MMK 38,553,359,871** (March 31, 2023: **MMK 22,861,298,326**).

**13. Other income**

	2024 MMK	2023 MMK
Sale of scrap	2,646,920	3,525,320
Interest income	2,003,590,608	432,782,595
Sales commission	46,594,956	–
Retainership fees	112,132,977	–
Disposal Gain	–	53,481
Other (Dossier License Fee income)	–	14,000,700
Foreign exchange gains	–	98,942,912
	<u>2,164,965,461</u>	<u>549,305,008</u>

**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED MARCH 31, 2024**

**14. Cost of materials consumed**

	2024 MMK	2023 MMK
Opening		
Raw materials	3,744,116,068	2,967,749,931
Packing materials	709,703,425	615,792,759
Add: Purchases		
Raw materials	9,402,044,259	5,419,631,623
Packing materials	1,114,387,861	915,497,972
	<u>14,970,251,613</u>	<u>9,918,672,285</u>
Less: Closing		
Raw materials	(6,189,460,835)	(3,744,116,068)
Packing materials	(515,318,367)	(709,703,425)
	<u>8,265,472,411</u>	<u>5,464,852,792</u>

**15. Change in inventories of finished goods and work in progress**

	2024 MMK	2023 MMK
Opening		
Work in progress	-	214,012,243
Finished goods	3,068,694,661	2,226,145,938
Less: Closing		
Work in progress	(61,881,257)	-
Finished goods	(3,426,870,754)	(3,068,694,661)
	<u>(420,057,350)</u>	<u>(628,536,480)</u>

**16. Employee benefits expense**

	2024 MMK	2023 MMK
Salaries and wages	2,049,041,012	1,585,878,994
Social security	11,233,650	8,747,700
Other employee expenses	266,292,832	198,969,260
	<u>2,326,567,494</u>	<u>1,793,595,954</u>

**17. Finance costs**

	2024 MMK	2023 MMK
Bank commission	10,431,180	13,497,320
Loan interest	559,301,989	139,708,381
Unrealized foreign exchange losses: borrowing	9,276,848,376	309,337,389
	<u>9,846,581,545</u>	<u>462,543,090</u>

**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED MARCH 31, 2024**

**18. Other expenses**

	<b>2024</b>	<b>2023</b>
	<b>MMK</b>	<b>MMK</b>
Product registration	7,785,680	23,610,279
Marketing expenses	10,607,958,039	6,051,740,089
Forex losses	12,638,030,976	-
Power	476,730,558	436,543,304
Fuel	291,071,644	558,382,050
Repair and maintenance	416,135,951	164,305,469
Consumables	575,709,589	474,981,651
Other operating costs	972,954,121	755,005,714
Printing and stationery	7,581,200	5,421,893
Legal and professional fees	10,925,000	4,334,253
Audit fees and expenses	18,384,900	15,999,100
Insurance expenses	63,024,017	66,227,043
Conveyance	341,762,450	265,225,232
Canteen expenses	151,886,840	97,809,300
Maintenance and administration charge	111,129,240	99,783,320
Guest house expenses	58,704,380	58,118,800
Internet expenses	17,847,700	16,259,000
Mobile expenses	8,705,707	6,592,000
Security service	25,200,000	23,040,000
Other general and admin expenses	516,312,940	369,931,245
Freight & forwarding on sales	982,487	101,622,667
	<b>27,318,823,419</b>	<b>9,594,932,409</b>

**19. Capital management**

The primary objective of the Company's capital management is to maintain a sufficient liquidity in order to support its business and maximize the shareholder value.

The Company manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants, if any.

**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED MARCH 31, 2024**

**20. Financial risk management**

The Company's activities expose it to market risks (including foreign exchange risk and interest rate risk), credit risk and liquidity risk. The Company's overall risk management strategy seeks to minimize potential adverse effects from the unpredictability of financial market on the financial performance of the Company. These policies and procedures are formulated, approved and regularly reviewed by the Board of Directors (the "Board").

The Board is responsible for setting the objective and underlying principles of financial risk management and providing an oversight of the entire risk management system of the Company. The management then establishes the detailed policies such as authority levels, oversight responsibilities, risk identification and measurement and exposure limits in accordance with the objectives and underlying principles approved by the Board.

**(a) Market risk**

**(i) Interest rate risk**

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of change in market interest rate. As at March 31, 2024, the Company is exposed to changes in market interest rates through borrowings at variable interest rates. The Company's investments in fixed deposits are at fixed interest rates.

**(ii) Foreign currency risk**

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of change in foreign currency rates. The Company's exposure to the risk of change in foreign currency rates relates primarily to the Company's operating activities (when revenue or expense is denominated in a different currency from the Company's functional currency).

**(b) Credit risk**

The maximum exposure to credit risk is represented by the carrying amount of the financial assets as stated in the statement of financial position.

**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED MARCH 31, 2024**

20. **Financial risk management** (continued)

(c) **Liquidity risk**

The Company's objective is to maintain a level of cash and bank balances deemed sufficient to finance the Company's operations and mitigate the effects of fluctuations in cash flows.

The table below summarizes the maturity profile of the Company's financial liabilities based on contractual undiscounted payments.

	<b>2024</b>			<b>2023</b>		
	<b>1 year or less MMK</b>	<b>1 - 3 years MMK</b>	<b>Total MMK</b>	<b>1 year or less MMK</b>	<b>1 - 3 years MMK</b>	<b>Total MMK</b>
Financial liabilities:						
Borrowing	–	<b>20,839,986,822</b>	<b>20,839,986,822</b>	–	6,621,313,922	6,621,313,922
Trade and other payables	<b>31,552,916,031</b>	–	<b>31,552,916,031</b>	6,738,872,832	–	6,738,872,832
<b>Total net undiscounted financial liabilities</b>	<b>31,552,916,031</b>	<b>20,839,986,822</b>	<b>52,392,902,853</b>	<b>6,738,872,832</b>	<b>6,621,313,922</b>	<b>13,360,186,754</b>

**ALIDAC HEALTHCARE (MYANMAR) LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED MARCH 31, 2024**

**21. Related party transactions**

In addition to the information disclosed elsewhere in the financial statements, the following transactions took place between the Company and related parties at terms agreed between the parties:

*(a) Purchase of goods, Service, Assets- related company (Zydus Lifesciences Limited) and Finance Costs {Zydus Worldwide DMCC (ZWWD)}*

Significant transactions during the year ended March 31, 2024 and 2023 were as follows:

	<b>2024</b>	2023
	<b>MMK</b>	MMK
For ZLL		
Purchase of materials	<b>7,353,956,226</b>	3,854,966,698
Purchase of services	<b>3,856,325,200</b>	–
Purchase of assets	–	209,300,082
For ZWWD		
Borrowing during the year	<b>4,941,824,524</b>	2,141,876,532
Finance costs (interest expenses)	<b>559,301,989</b>	139,708,381

Outstanding balances at March 31, 2024 and 2023, arising from purchase of goods and services are unsecured and payable within 12 months from balance sheet date and are disclosed in Notes 7 and 11 respectively.

*(b) Key management personnel compensation*

	<b>2024</b>	2023
	<b>MMK</b>	MMK
Salaries and allowances	<b>577,113,170</b>	433,909,073

**22. Authorization of financial statements**

These financial statements were authorized for issue in accordance with a resolution of the Board of Directors of the Company on May 17, 2024.